PARTNERING OPPORTUNITIES
Bionomics has a lengthy history of successful alliances with industry and academia. In general, the company seeks to develop compounds to successful proof of concept in human clinical trials. We are open to expressions of interest with respect to partnership at all stages of development.
Additionally, Bionomics is open to in-licensing proposals that are in alignment with the company’s overall therapeutic focus in CNS diseases.
Pre-Clinical CNS Assets
Kv3.1/3.2 Program
Small molecule Kv3.1 / Kv3.2 potassium ion channels activators for improving cognitive dysfunction and negative symptoms in schizophrenia and other illnesses such as Autism Spectrum Disorder and Alzheimer’s Disease
Nav Program
Small molecule pan Nav (1.7/1.8/1.9) inhibitors for the treatment of chronic pain
Oncology
BNC105
A multi-modal small molecule tubulin polymerization inhibitor has completed four Phase 1 and Phase 2 clinical trials
BNC101
A humanized monoclonal antibody to LGR5, a cancer stem cell receptor has completed Phase 1 clinical trials
For any partnering enquiries, please contact us here